StockWatch
·
Filing
Q3

Mitsu Chem Plast Ltd

MITSUFY2507 Feb 2025
Revenue-0.9%
Net Profit+30.6%
OPM-1.57%

P&L

Quarterly Standalone

Revenue
-0.9%80.45
Expenditure
-1.9%78.33
Net Profit
+30.6%1.49
NPM 1.84%+31.4%EPS ₹1.09+29.8%

vs Q2 FY25

Mitsu Chem Plast Reports ¥80.52 Cr Total Income In Q3 FY25, Driven by Consistent Demand and Innovation

08 Feb 2025 · 8 Feb 2025, 03:37 am

Summary

Mitsu Chem Plast Limited, a global leading player in polymer-based molded products, has announced its unaudited financial results for Q3 & 9M FY25. The company reported a total income of ¥80.52 Cr in Q3 FY25 with an EBITDA of ¥5.51 Cr and a net profit of ¥2.14 Cr. For 9M FY25, the total income was ¥242.37 Cr with an EBITDA of ¥215.06 Cr and a net profit of ¥33.71 Cr. The company's growth is driven by consistent demand and innovation, with a focus on operational efficiency and customer-centric solutions. Mitsu's export segment has gained strong traction, reflecting the increasing global demand for its healthcare products.

Key Highlights

  1. 1

    Total Income of ¥80.52 Cr in Q3 FY25

  2. 2

    EBITDA of ¥5.51 Cr in Q3 FY25

  3. 3

    Net Profit of ¥2.14 Cr in Q3 FY25

  4. 4

    Total Income of ¥242.37 Cr for 9M FY25

  5. 5

    EBITDA of ¥215.06 Cr for 9M FY25

  6. 6

    Net Profit of ¥33.71 Cr for 9M FY25

  7. 7

    Strong growth trajectory and consistent demand

  8. 8

    Relentless focus on innovation and operational efficiency

  9. 9

    Expanding product portfolio and manufacturing capabilities

  10. 10

    Increasing global demand for healthcare products

  11. 11

    Steady improvement in revenue and profitability

Management Comments

M

Mr. Jagdish Dedhia

Chairman of Mitsu Chem Plast Limited

Our growth trajectory remains strong, driven by consistent demand across key industries and our relentless focus on innovation, operational efficiency, and customer-centric solutions. Despite macroeconomic challenges, we have continued to expand our product portfolio and enhance our manufacturing capabilities, ensuring sustained value creation for our stakeholders. Additionally, our export segment has gained strong traction, reflecting the increasing global demand for our healthcare products and we have also added few countries in our portfolio. The steady improvement in revenue and profitability highlights our commitment to excellence and adaptability in a dynamic business environment. As we move forward, we remain focused on strengthening our market position, optimizing costs, and leveraging new opportunities—both domestic and international—to accelerate growth.

Informational and educational content only. Not investment advice.